Product nameAnti-NAGLU/NAG antibody
See all NAGLU/NAG primary antibodies
DescriptionRabbit polyclonal to NAGLU/NAG
Tested applicationsSuitable for: ICC/IF, IHC-P, WBmore details
Species reactivityReacts with: Mouse, Human
Predicted to work with: Cow, Chimpanzee, Rhesus monkey
Synthetic peptide corresponding to Human NAGLU/NAG aa 1-100 conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in HepG2 Whole Cell Lysate
This product was previously labelled as NAGLU
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Immunizing Peptide (Blocking)
Our Abpromise guarantee covers the use of ab72178 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use a concentration of 5 µg/ml.|
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 82 kDa (predicted molecular weight: 82 kDa).|
FunctionInvolved in the degradation of heparan sulfate.
Tissue specificityLiver, ovary, peripheral blood leukocytes, testis, prostate, spleen, colon, lung, placenta and kidney.
Involvement in diseaseDefects in NAGLU are the cause of mucopolysaccharidosis type 3B (MPS3B) [MIM:252920]; also known as Sanfilippo syndrome B. MPS3B is a form of mucopolysaccharidosis type 3, an autosomal recessive lysosomal storage disease due to impaired degradation of heparan sulfate. MPS3 is characterized by severe central nervous system degeneration, but only mild somatic disease. Onset of clinical features usually occurs between 2 and 6 years; severe neurologic degeneration occurs in most patients between 6 and 10 years of age, and death occurs typically during the second or third decade of life.
- Information by UniProt
- Alpha N acetylglucosaminidase antibody
- alpha N acetylglucosaminidase, lysosomal antibody
- Alpha-N-acetylglucosaminidase 77 kDa form antibody
Anti-NAGLU/NAG antibody (ab72178) at 1 µg/ml + HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate at 10 µg
Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 82 kDa
Observed band size: 82 kDa
ICC/IF image of ab72178 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab72178, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM. This antibody also gave a positive result in 4% PFA fixed (10 min) Hek293 and HepG2 cells at 5ug/ml and in 100% methanol fixed (5 min) MCF7 cells at 5µg/ml.
This product has been referenced in:
- Yang Q et al. A model of mucopolysaccharidosis type IIIB in pigs. Biol Open 7:N/A (2018). Read more (PubMed: 30257828) »
- Kan SH et al. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proc Natl Acad Sci U S A 111:14870-5 (2014). Mouse . Read more (PubMed: 25267636) »